These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25481459)

  • 21. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.
    Zelenitsky S; Nash J; Weber Z; Iacovides H; Ariano R
    J Chemother; 2016 Oct; 28(5):390-4. PubMed ID: 27077931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol.
    Tschudin-Sutter S; Frei R; Widmer AF
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):286-7. PubMed ID: 21353954
    [No Abstract]   [Full Text] [Related]  

  • 24. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.
    Kuck NA; Petersen PJ; Weiss WJ; Jacobus NV; Testa RT; Tally FP
    J Chemother; 1989 Jul; 1(4 Suppl):105-6. PubMed ID: 16312325
    [No Abstract]   [Full Text] [Related]  

  • 25. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
    Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
    J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
    Yamagishi Y; Terada M; Ohki E; Miura Y; Umemura T; Mikamo H
    J Infect Chemother; 2012 Feb; 18(1):127-9. PubMed ID: 21814800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.
    Moet GJ; Watters AA; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):319-22. PubMed ID: 19822271
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Stainton SM; Monogue ML; Nicolau DP
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28607019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
    Monogue ML; Nicolau DP
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7527-7529. PubMed ID: 27799205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of generic formulation of piperacillin/tazobactam (Astaz-P) for treatment of infected patients at Siriraj Hospital.
    Charoenpong L; Tongsai S; Thamlikitkul V
    J Med Assoc Thai; 2013 Feb; 96 Suppl 2():S104-10. PubMed ID: 23590029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.
    Zuluaga AF; Rodriguez CA; Agudelo M; Vesga O
    BMC Res Notes; 2015 Oct; 8():546. PubMed ID: 26445936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Fujimura S; Takane H; Nakano Y; Watanabe A
    J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.
    Felton TW; Goodwin J; O'Connor L; Sharp A; Gregson L; Livermore J; Howard SJ; Neely MN; Hope WW
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5811-9. PubMed ID: 24002098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.